Safety profile of crizanlizumab 5.0 mg/kg in sickle cell disease: pooled data from clinical trials
- Abdullah Kutlar
- , Vikas Joshi
- , Andreas Brueckner
- , Julie Kanter
- , Darla Liles
- , Jeremie Lincy
- , Rahul Manjare
- , Yvonne Dei-Adomakoh
- , Michele Nassin
- , Matthew M. Heeney
- , Mariane De Montalembert
- , Deborah Lynn Keefe
- , Kwaku Marfo
- , Kenneth I. Ataga
- Medical College of Georgia
- Novartis
- Novartis International AG
- University of Alabama at Birmingham
- East Carolina University
- Novartis Pharmaceuticals Corporation
- Harvard Medical School
- Assistance Publique—Hopitaux de Paris Centre
- IQVIA Research and Development Solutions
- University of Tennessee Health Science Center
Research output: Contribution to journal › Article › peer-review